Brief: Armata Pharma Gets FDA IND Clearance For Phase 1B/2A Study Of Staphylococcus Aureus Bacteremia Treatment
18/11/2021 13:20
Nov 18 (Reuters) - Armata Pharmaceuticals Inc ARMP.A :
* ARMATA PHARMACEUTICALS PROVIDES REGULATORY AND CLINICAL
UPDATE
REFLECTING SUSTAINED PROGRESS ACROSS KEY PHAGE THERAPEUTIC
DEVELOPMENT PROGRAMS
* ARMATA PHARMACEUTICALS INC - ANNOUNCES FDA CLEARANCE OF
IND TO
INITIATE PHASE 1B/2A CLINICAL TRIAL OF AP-SA02 IN STAPHYLOCOCCUS
AUREUS BACTEREMIA
* ARMATA PHARMACEUTICALS INC - EXPECTS TO INITIATE A PHASE
1B/2A
CLINICAL STUDY OF AP-SA02 BY END OF THIS YEAR
Source text for Eikon: ID:nPn8H2H4ka
Further company coverage: ARMP.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Armata Pharmaceuticals
See all newsBrief: Armata Pharmaceuticals Announces First Quarter 2026 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Delays Announcement Of Fourth Quarter And Full-Year 2025 Results And Provides Corporate Update
Brief: Armata Pharmaceuticals Receives FDA Qualified Infectious Disease Product Designation
Armata Pharma jumps on US FDA nod for late-stage infection trial
Brief: Armata Pharmaceuticals Commissions cGMP Manufacturing Facility In Los Angeles